

84[™] ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION October 29 - November 2, 2014 Hotel Del Coronado, Coronado, California www.thyroid.org

MEETING PROGRAM (as of 10/20/2014) Information subject to change

| Wednesday, October 29, 2014 | | |
|---|--|--|
| Registration Open 2:00 PM – 8 :30 PM Exhibit Hall Open 7:30 PM – 9:00 PM | | |
| ATA/AACE Advanced Endocrine Neck Ultrasound Course 7:00 AM – 5:00 PM Chairs: Susan Mandel and Robert Levine | | |
| E. Chester Ridgway Trainee Conference 7:00 AM – 5:00 PM Chairs: Andrew Gianoukakis and Stephanie Fish | | |
| Welcome/Opening Remarks 5:30 PM – 5:45 PM Hossein Gharib, ATA President John C. Morris, III, Secretary/COO R. Michael Tuttle, Program Co-Chair Fredric Wondisford, Program Co-Chair | | |
| Opening Session: Recent Developments and Future Challenges in Thyroidology 5:45 PM – 7:30 PM Chairs: R. Michael Tuttle and Fredric Wondisford | | |
| Basic: Peter Kopp Clinical: Douglas Ross Surgical: Herb Chen | | |

ATA Welcome Reception 7:30 PM - 9:00 PM

| 84th Annual Meeting of the ATA Thursday, October 30, 2014 | | |
|--|---|--|
| | 6:30 AM – 5:30 PM | |
| Registration open | 0.50 mm 5.50 mm | |
| | Thyroid Cancer 6:45 AM – 8:00 AM | |
| Chair: Jer | nifer Sipos | |
| Prophylactic Thyroidectomy in MEN2: When and Why? Steven Waguespack Management of Persistent/Recurrent Disease in the Neck Jeffrey Moley Management of Persistent/Recurrent Disease in Distant Sites Manisha Shah | | |
| | Implications of Incidental Germ Line Findings | |
| Discovered as Part of Sequencing Studies 8:10 AM – 8:55 AM Introduction: R. Michael Tuttle Speaker: Mark Robson | | |
| | on (4 total) 9:00 AM – 10:00 AM | |
| | e and Fredric Wondisford | |
| Highlighted Oral Abstract 1, Autoimmunity, Clinical DOUBLE VISION IS THE MOST COMMON INDICATION FOR THERAPY IN MODERATE TO SEVERE GRAVES' ORBITOPATHY BUT IT CORRELATES NEGATIVELY WITH INFLAMMATORY SIGNS AND PROPTOSIS. A SINGLE CENTER PROSPECTIVE COHORT STUDY (N=215) WITH OBJECTIVE QUANTITATION OF DIPLOPIA Peter Laurberg , D.C. Berman, I.B. Pedersen, S. Andersen, A. Carlé Highlighted Oral Abstract 2, Autoimmunity, Translational CRYSTAL STRUCTURE OF A TSH RECEPTOR MONOCLONAL ANTIBODY PROVIDES EVIDENCE THAT A TRIMER OF THE SHED RECEPTOR A-SUBUNIT IS THE CRITICAL IMMUNOGEN IN GRAVES' DISEASE Chun-Rong Chen , P. Hubbard, S.M. McLachlan, R. Murali, B. Rapoport | | |
| Highlighted Oral Abstract 3, Autoimmunity, Translational DEVELOPMENT OF A UNIQUE MOUSE MODEL FOR GRAVES' DISEASE THAT SPONTANEOUSLY DEVELOPS PATHOGENIC TSH RECEPTOR ANTIBODIES Sandra M. McLachlan, H. Aliesky, B. Banuelos, B. Rapoport Highlighted Oral Abstract 4, Thyroid & Development, Basic DIFFERENTIATION OF HUMAN EMBRYONIC STEM (HES) CELLS INTO THYROID CELLS Risheng Ma, R. Latif, T.F. Davies | | |
| | 10:00AM – 4:30 PM ne Exhibit Hall 10:00 AM – 11:00 AM | |
| Poster Review Session and Break in th | 1000 AM = 11000 AM | |
| Meet the Professor Workshop | s (5 total) 11:00 AM – 12:00 PM | |
| Clinical | Basic/Translational | |
| Thyroid Disease and Pregnancy Robin Peeters Management of Persistent/Recurrent Differentiated Thyroid Cancer: When to Treat, When to Watch? Mona Sabra and Gary Clayman TSH Suppression in Thyroid Cancer: Optimizing Risks vs. Benefits Irwin Klein and Anne Cappola Fukushima Daiichi Accident and Thyroid Cancer Shigenobu Nagataki | Genome Wide Analysis of Signaling Laurent Sachs In Vivo Modulation of Thyroid Hormone Action by Cofactors Anthony Hollenberg | |
| Lunch and Poster Review on Y | Tour Own 12:00 PM – 12:55 PM | |
| ATA Committee Meetings Luncheon (for 2014 ATA Committee members) 12:00 PM – 12:55 PM | | |
| ATA Expo Theater with Bayer Healthcare/Onyx Pharmaceuticals 12:00 PM – 12:55 PM NEXAVAR® (sorafenib) in Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Treatment: The Phase 3 DECISION Trial (Open to all attendees; space limited – first come, first served) Speaker: Ezra Cohen, MD | | |
| Sidney H. Ingbar Award Lecture: Role of Thyroid Hormones in Skeletal Development and Bone Maintenance 1:00 PM – 1:45 PM Introduction: Sheue-yann Cheng Speaker: Graham Williams | | |

84th Annual Meeting of the ATA Thursday, October 30, 2014 (continued)

| Thursday, October 30, 2014 (continued) | | | |
|---|---|--|--|
| Oral Abstract Sessions 1:50 PM – 3:20 PM | | | |
| Clinical (6 total) | Basic/Translational Research Awards (6 total) | | |
| Chairs: Naifa Busaidy and Wendy Sacks | Chairs: Ronald Koenig and Yun-Bo Shi | | |
| Oral Abstract 11 Thursd Causan Clinical | Oral Abatraat 5 Thursd Canoon Davis | | |
| Oral Abstract 11, <i>Thyroid Cancer, Clinical</i> LONG-TERM MODERATE THYROID HORMONE SUPPRESSION | Oral Abstract 5, <i>Thyroid Cancer , Basic</i> KRASG12D MEDIATED ONCOGENIC TRANSFORMATION OF | | |
| THERAPY IS ASSOCIATED WITH IMPROVED OUTCOMES IN | THYROID FOLLICULAR CELLS REQUIRES LONG-TERM TSH | | |
| DIFFERENTIATED THYROID CARCINOMA: NATIONAL | STIMULATION AND IS REGULATED BY SPRY1 Yufei Shi, M. | | |
| THYROID CANCER TREATMENT COOPERATIVE STUDY | Zou, E. Baitei, R. Al-Rijjal, R. Parhar, F. Al-Mohanna, S. Kimura, C. | | |
| GROUP REGISTRY ANALYSIS 1987-2012 Aubrey Carhill, D.R. | Pritchard, A. Alzahrani, A. Assiri, B. Meyer | | |
| Litofsky, K. Ain, J. Brierley, D.S. Cooper, H. Fein, B. Haugen, J. Jonklaas, P. Ladenson, J. Magner, D. Ross, M. Skarulis, D. Steward, | Oral Abstract 6, Thyroid Cancer, Basic | | |
| M. Xing, H. Maxon, S.I. Sherman | SEX HORMONES REGULATE THYROID CANCER INITIATION | | |
| | AND PROGRESSION BY MODIFYING TUMOR SUPPRESSOR | | |
| Oral Abstract 12, Autoimmunity, Clinical | GENE EXPRESSION AND TUMOR IMMUNITY Lisa J. Zhang, Y. | | |
| INDUCTION OF PAINLESS THYROIDITIS IN PATIENTS RECEIVING PROGRAMMED DEATH 1 RECEPTOR | Xiong, N. Nilubol, M. He, S. Bommareddi, X. Zhu, L. Jia, Z. Xiao, J. | | |
| IMMUNOTHERAPY FOR METASTATIC MALIGNANCIES | Park, X. Xu, D. Patel, M.C. Willingham, S. Cheng, E. Kebebew | | |
| S. Orlov, F. Salari, L. Kashat, J. Alfaifi, Paul G. Walfish | Oral Abstract 7, Thyroid Cancer, Basic | | |
| | COOPERATIVE ACTIVATION OF TERT BY BRAF V600E AND | | |
| Oral Abstract 13, <i>Thyroid Cancer, Clinical</i> | TERT PROMOTER MUTATIONS: A NOVEL MOLECULAR | | |
| PROGNOSTIC AND PREDICTIVE FACTORS CORRELATED WITH TREATMENT OUTCOMES FOR RADIOACTIVE IODINE- | MECHANISM IN THYROID TUMORIGENESIS Rengyun Liu , <i>M. Xing</i> | | |
| REFRACTORY DIFFERENTIATED THYROID CANCER (RAI- | Amg | | |
| RDTC) PATIENTS RECEIVING SORAFENIB OR PLACEBO ON | Oral Abstract 8, Iodine Uptake & Metabolism, Basic | | |
| THE PHASE III DECISION TRIAL Martin Schlumberger, R. | EFFECTIVE ¹³¹ I THERAPY OF METASTATIC COLON CANCER | | |
| Elisei, F. Pacini, B. Jarzab, L. Giannetta, L. Bastholt, C. De la Fouchardiere, R. Paschke, F. Worden, Y. Shong, J. Smit, C. Kappeler, | AFTER MESENCHYMAL STEM CELL-MEDIATED TUMOR STROMA TARGETING OF THE SODIUM IODIDE SYMPORTER | | |
| I. Molnar, M.S. Brose | K. Knoop, N. Schwenk, K.A. Schmohl, A. Mueller, C. Zach, C. Cyran, | | |
| | J. Carlsen, G. Böning, P. Bartenstein, B. Göke, E. Wagner, P.J. | | |
| Oral Abstract 14, Thyroid Cancer, Clinical | Nelson, Christine Spitzweg | | |
| IS PREOPERATIVE VITAMIN D DEFICIENCY A RISK FACTOR | | | |
| FOR POSTOPERATIVE SYMPTOMATIC HYPOCALCEMIA IN THYROID CANCER PATIENTS UNDERGOING TOTAL | Oral Abstract 9, <i>Thyroid Cancer, Basic</i> BRAF ACTIVATES AND PHYSICALLY INTERACTS WITH PAK | | |
| THYROID CARCER FATILITY ONDERGOING TOTAL THYROIDECTOMY PLUS CENTRAL COMPARTMENT NECK | TO REGULATE CELL MOTILITY Samantha K. McCarty, M. | | |
| DISSECTION? W. Kim, J. Jeong, S. Jung, C. Lee, S. Kang, J. Lee, J. | Saji, X. Zhang, L.S. Kirschner, S. Fernandez, M.D. Ringel | | |
| Jung, Kee Hyun Nam, W. Chung, C. Park | | | |
| Oral Abstract 15, Thyroid Cancer, Clinical | Oral Abstract 10, <i>Thyroid Cancer, Basic</i> BRAF ^{V600E} -DRIVEN MURINE ANAPLASTIC THYROID | | |
| IMPACT OF RADIOACTIVE IODINE ON SURVIVAL IN | CANCERS RECUR AFTER WITHDRAWAL OF THE | | |
| PAPILLARY THYROID CARCINOMA | ONCOPROTEIN, AND REACTIVATE MAPK SIGNALING IN A | | |
| D. Boone, Paritosh Suman, R. Prinz, T. Moo-Young, D.J. Winchester | BRAF ^{V600E} -INDEPENDENT MANNER Jeffrey A. Knauf, K. Chen, | | |
| Oral Abstract 16, Thyroid Cancer, Clinical | R.A. Ghossein, J. Fagin | | |
| POSTOPERATIVE NOMOGRAM FOR PREDICTING CANCER- | | | |
| SPECIFIC MORTALITY IN MEDULLARY THYROID CANCER | | | |
| A.S. Ho, L. Wang, F.L. Palmer, C. Yu, A. Toset, S.G. Patel, M.W. | | | |
| Kattan, M.R. Tuttle, Ian Ganly Postor Poviow Session and Break in | the Exhibit Hall 3:20 PM – 3:50 PM | | |
| | ia $3:50 \text{ PM} - 5:05 \text{ PM}$ | | |
| Clinical: Voice Symposium, Surgically Related | Basic: Thyroid Cell Biology | | |
| Chair: Amy Chen | (Dedicated to the Memory of Paul Kim) | | |
| | Chair: Fredric Wondisford | | |
| Getting the Most Out of the New Guidelines | | | |
| (ATA and AAO-HNSF) David Terris | To Be or Not to Be: How Thyroglobulin Mutations and | | |
| Novel Ways to Image Vocal Cord Function | Folding Affect Thyroid Survival and Growth Peter Arvan | | |
| Denise Carneiro-Pla | Unraveling the Mysteries of the Sodium Iodide | | |
| State of the Science: Use of Intraoperative Nerve Monitoring | Symporter (NIS) Nancy Carrasco | | |
| and Prediction of Long Term Outcomes Quan-Yang Duh | Physiology and Pathophysiology of the Dual Oxidases DUOX1 and 2 Xavier De Deken | | |
| | | | |
| Symposium: Intersecting Autoimmunity, Immuno-Modulators and Thyroid Dysfunction – Updates and Emerging Themes 5:10 PM – 6:25 PM | | | |
| Chair: Terry Davies | | | |
| onun Tony Dunio | | | |
| Thyroid Dysfunction as a Component of Autoimmune Polyendocrinopathy Syndrome George Kahaly | | | |
| Thyroid Dysfunction Associated with Other Autoimmune Diseases Kristien Boelaert | | | |
| Thyroid Dysfunction Associated with Immune Modulating Therapies Mabel Ryder | | | |
| | eeting 6:30 PM – 7:30 PM | | |
| (for ATA Active and senior members only) | | | |
| FREE EVENING | | | |

| | eting of the ATA | |
|---|---|--|
| | bber 31, 2014 | |
| <u> </u> | 6:30 AM – 5:30 PM | |
| Early Riser Symposium: Radioactive Iodine Remnant Ablation: Selecting the Proper Patients, | | |
| Preparation Method and Administered Activity 6:45 AM – 8:00 AM | | |
| Chair: Laura Boucai | | |
| | | |
| | ted Thyroid Cancer Fabian Pitoia | |
| | active Iodine Ablation Leonard Wartofsky | |
| | e Learn, What Is Next? Ujjal Mallick | |
| | 8:10 AM – 8:55 AM | |
| | e announced onsite | |
| Speaker: To be announced onsite | | |
| | ia 9:00 AM – 10:15 AM | |
| Clinical: ICCIDD Iodine Deficiency Symposium | Basic: Thyroid Hormone Regulation of | |
| (Dedicated to the Memory of Gerard "Gerry" Burrow) | Growth and Development | |
| Chairs: Elizabeth Pearce and Angela Leung | Chair: Anthony Hollenberg | |
| | | |
| Iodine in Veterinary Populations Charlene Edinboro | Thyroid Hormone and the Auditory System Douglas Forrest | |
| David Marine and the Elimination of Endemic Goiter in the | The Role of Thyroid Hormone on Cerebral Cortex | |
| United States J. Woody Sistrunk | Development Beatriz Morte Molina | |
| | Roles of Thyroid Hormone Receptors in the Regulation | |
| | of Thyroid Growth Sheue-yann Cheng | |
| Evhibit Hall Open | 10:00 AM – 4:30 PM | |
| EXILIULI Hall Open Poster Review Session and Break in the | The Exhibit Hall 10:15 AM $-$ 11:15 AM | |
| | a 11:15 AM – 12:30 PM | |
| Arthur Bauman Clinical Symposium: | Basic: The Journey of Thyroid | |
| Behind the Scenes - Difficult Decisions, Controversies | Hormone into the Cell Nucleus | |
| | | |
| and Logic in Developing ATA Guidelines | Chair: Sheue-yann Cheng | |
| Chair: Glenn Braunstein | | |
| | Cell Membrane Transporter Heike Heuer | |
| Thyroid Nodules and Differentiated Thyroid Cancer | Cellular Deiodinase Regulation Elizabeth McAninch | |
| Guidelines Bryan Haugen | Role of Transthyretin in Placental Thyroid Hormone | |
| Medullary Thyroid Cancer Guidelines Samuel Wells | Transport Kerry Richard | |
| Hypothyroidism Guidelines: To T3 or Not to T3 and Other | | |
| Questions About the Treatment of Hypothyroidism | | |
| Jacqueline Jonklaas | | |
| Lunch and Poster Review on Y | Your Own 12:30 PM – 1:25 PM | |
| | | |
| ATA Women in Thyroidology Netw | rorking Meeting 12:30 PM – 1:25 PM | |
| | | |
| | acyte, Inc 12:30 PM – 1:25 PM | |
| | Afirma Thyroid FNA Analysis | |
| | limited – first come, first served) | |
| Speakers: Giulia C. Ken | nedy and Richard T. Kloos | |
| | Iodines: And the Braverman/Wartofsky Intersection | |
| 1:30 PM–2:15 PM | | |
| Introduction: Elizabeth Pearce | | |
| Speaker: Leonard Wartofsky | | |
| Meet the Professor Workshops (5 total) 2:20 PM – 3:20 PM | | |
| Clinical | Translational/Basic | |
| | | |
| • Serum Thyroglobulin in the Management of | ATA Basic Research Guidelines: How to Manipulate | |
| Differentiated Thyroid Cancer: An Update in 2014 | Thyroid Status in Animal Models Tania Ortiga-Carvalho | |
| Carole Spencer and Robert Smallridge | Role of TRs in Cell Differentiation and Senescence | |
| • Evaluation of Thyroid Nodules: What is the Role of | Ana Aranda | |
| Molecular Markers? Julie Ann Sosa and Anna Sawka | | |
| Evaluation and Management of Thyroid Nodules and | | |
| | | |
| Thyroid Cancer in the Pediatric Population Stephen | | |
| Huang | | |
| Clark T. Sawin Historical Vignette: Theodor Kocher (1841-1917) – A Lasting Legacy 3:25 PM – 3:50 PM | | |
| Introduction: Jeffrey Garber | | |
| Speaker | Peter Kopp | |
| | | |
| | eak 3:50 PM – 4:20 PM | |

84th Annual Meeting of the ATA *Friday, October 31, 2014 (continued)*

| | 1, 2014 (continued) | |
|---|--|--|
| Research Grants Sympo | osium 4:20 PM – 5:05 PM | |
| Chair: Mir | ngzhao Xing | |
| | | |
| | ipid Modulation by Thyroid Hormone Stephen Ayers | |
| | Heart Failure Ari J. Wassner | |
| Sorafenib and Quinacrine as Potential Combination for Anaplastic Thyroid Carcinoma Niklas Finnberg Oral Abstract Sessions 5:10 PM- 6:40 PM | | |
| | | |
| Clinical (6 total) Chairs: Kenneth Ain and Brian Kim | Basic/Translational (6 total) | |
| Chairs: Kennein Ain and Brian Kim | Chairs: Terry Davies and Theo Visser | |
| Oral Abstract 121, Thyroid Cancer, Translational | Oral Abstract 115, Thyroid Cancer, Basic | |
| TUMOR SUPPRESSOR MIR-30A-5P INHIBITS LOX | MICRORNA-339-5P MODULATES NA ⁺ /I ⁻ SYMPORTER- | |
| EXPRESSION AND CANCER PROGRESSION IN | MEDIATED RADIOIODIDE UPTAKE Aparna | |
| THYROID CANCER Myriam Boufragech, N. nilubol, L. | Lakshmanan, A. Wojcicka, M. Kotlarek, K. Jazdzewski, S.M. | |
| Zhang, S. gara, S. Sadowski, A. Mehta, M. He, S. davis, J. | Jhiang | |
| Dreiling, J.A. Copland, R.C. Smallridge, M. Quezado, E. | | |
| Kebebew | Oral Abstract 116, Thyroid Cancer, Basic | |
| | TARGETED DELIVERY OF A NOVEL HISTONE | |
| Oral Abstract 122, Thyroid Cancer, Translational | DEACETYLASE INHIBITOR, AB3, USING | |
| DETECTION OF CIRCULATING BRAFV600E IN | UNIMOLECULAR MICELLES TO IMPROVE | |
| PATIENTS WITH PAPILLARY THYROID CARCINOMA | ANTITUMOR EFFECT IN MEDULLARY THYROID | |
| Carrie C. Lubitz, S. Parangi, M. Bernasconi, A.P. Schalck, | CANCER Renata Jaskula-Sztul, G. Chen, A.D. Harrison, A. | |
| D.T. Frederick, H. Suh, S.E. Donovan, L. Wirth, R.J. Sullivan, | Dammalapati, R. Nair, G. Winston-McPherson, C. | |
| D.J. Panka | Scheinebeck, W. Tang, S. Gong, H. Chen | |
| | | |
| Oral Abstract 123, <i>Thyroid Cancer, Clinical</i> | Oral Abstract 117, Autoimmunity, Basic | |
| HIGHLY ACCURATE DIAGNOSIS OF CANCER IN THYROID NODULES WITH FOLLICULAR | STANDARDIZATION OF A FDA-CLEARED BIOASSAY CONVERTS THYROID-STIMULATING ANTIBODY | |
| NEOPLASM/SUSPICIOUS FOR A FOLLICULAR | LEVELS INTO INTERNATIONAL UNITS ENABLING | |
| NEOPLASM CYTOLOGY BY THYROSEQ V2 NEXT | COMPARISON AMONG LABORATORIES Tanja Diana, | |
| GENERATION SEQUENCING ASSAY Yuri Nikiforov, | M. Kanitz, M. Lehmann, J. Franken, G.J. Kahaly | |
| S.E. Carty, S.I. Chiosea, C. Coyne, U. Duvvuri, R.L. Ferris, S. | ni. Hanne, ni. Dennann, e. i ranken, e.e. Hanary | |
| Hodak, S.O. LeBeau, N. Ohori, R.R. Seethala, M.E. Tublin, L. | Oral Abstract 118, Thyroid Hormone Action, Basic | |
| Yip, M. Nikiforova | THYROID HORMONE INTERACTS WITH ALPHA2C | |
| | ADRENERGIC RECEPTOR SIGNALING TO REGULATE | |
| Oral Abstract 124, Thyroid Cancer, Translational | THE EPIPHYSIAL GROWTH PLATE MORPHOLOGY | |
| MUTATIONAL ANALYSIS OF KINOME IN | AND BONE GROWTH Manuela M. Rodrigues, M.V. Silva, | |
| DIFFERENTIATED THYROID CANCER Tae Hyuk Kim, | P.C. Brum, C.H. Gouveia | |
| J. Park, D. Park, K. Lee, J. Moon, K. Kim, K. Yi, D. Park, Y. | | |
| Park | Oral Abstract 119, Disorders of Thyroid Function, Basic | |
| | TSH RECEPTOR ENDOCYTIC CARGO DETERMINES | |
| Oral Abstract 125, <i>Thyroid Cancer, Clinical</i> | THYROCYTE CELL FATE Syed A. Morshed, R. Ma, R. | |
| DEVELOPMENT OF A CLINICAL TARGETED NEXT- | Latif, T.F. Davies | |
| GENERATION SEQUENCING TEST FOR INDETERMINATE THYROID NODULES Shih-Min | Oral Abstract 120 Thuraid Hormona Matchelian & | |
| Cheng, D. Lew, C. Barlan, F.M. Hantash, J.J. Catanese, A. | Oral Abstract 120, <i>Thyroid Hormone Metabolism &</i> Regulation, Basic | |
| Grupe, D. Ross, R.E. Reitz, F.M. Waldman | PHARMACOLOGICAL ACTIVATION OF THYROID | |
| 01 apc, D. 1055, 11.D. 1012, 1 .51. Wulunun | HORMONE RECEPTORS ELICITS A FUNCTIONAL | |
| Oral Abstract 126, Thyroid Cancer, Translational | CONVERSION OF WHITE TO BROWN FAT Kevin | |
| IDENTIFICATION OF IODINE METABOLISM- | Phillips, J.Z. Lin, A.J. Martagón, S.L. Cimini, D.D. Gonzalez, | |
| ASSOCIATED LARGE NON-CODING RNA (LINCRNA) | S.M. Hartig, A. Biter, N. Zhang, J.D. Baxter, P. Webb, J. | |
| DIFFERENTIALLY EXPRESSED IN BRAFV600E- | Gustafsson | |
| POSITIVE PAPILLARY THYROID CANCER VERSUS | | |
| NORMAL THYROID TISSUE M. Duquette, A. Fischer, E. | | |
| Puxeddu, J. Lawler, P. Pandolfi, Carmelo Nucera | | |
| | | |
| ATA Annual Bananat 7:20 DM | $1.00 \text{ DM} (A d \dots d \dots d h d h d h d h d h d h h h h h$ | |

ATA Annual Banquet 7:30 PM – 11:00 PM (Admission with ticket only)

| | eting of the ATA | |
|--|---|--|
| Saturday, November 1, 2014 | | |
| | 6:30 AM – 5:30 PM ed Radioactive Iodine Refractory Thyroid Cancer | |
| | - 8:00 AM | |
| | E. Cabanillas | |
| | | |
| | ve Iodine Refractory? Stephanie Lee | |
| | ies in Radioiodine-Refractory Thyroid Cancers Keith Bible ch Agents and When? Rossella Elisei | |
| | d Thyrotroph Cell Death 8:10 AM – 8:55 AM | |
| | : Yun-Bo Shi | |
| Speaker: Rolf Karlstrom | | |
| | 6 total) 9:00 AM – 10:30 AM | |
| Chairs: Elizabeth Pear | rce and Antonio Bianco | |
| Short Call Oral 1, <i>Thyroid Cancer, Translational</i> TERT PROMOTER AND BRAF MUTATIONS COOPERATIVELY PROMOTE PAPILLARY THYROID CANCER- RELATED MORTALITY Mingzhao Xing , <i>R. Liu, J. Bishop</i> | | |
| Short Call Oral 2, <i>Thyroid Cancer, Basic</i> NF2/MERLIN IS A NOVEL THYROID TUMOR SUPPRESSOR GENE WHOSE LOSS PROMOTES ONCOGENIC RAS- INDUCED THYROID CANCERS VIA YAP-DEPENDENT TRANSACTIVATION OF MUTANT RAS AND SENSITIZES THEM TO MEK INHIBITION Maria E. Garcia-Rendueles, J. Ricarte Filho, B.R. Untch, J.A. Knauf, V. Smith, E. Lundsmith, B. Taylor, G. Oler, S.C. Jhanwar, A. Viale, F. Giancotti, Y. Fang, A. Heguy, K.H. Huberman, M. Ryder, R.A. Ghossein, J. Fagin | | |
| Short Call Oral 3, <i>Thyroid Cancer, Translational</i> TARGETING OF ONCOGENIC HRAS IN MURINE AGGRESSIVE THYROID CANCERS WITH MEK AND FARNESYLTRANSFERASE INHIBITION Brian R. Untch , J.A. Knauf, M.E. Garcia-Rendueles, R.A. Ghossein, A.L. Ho, J. Fagin | | |
| Short Call Oral 4, <i>Autoimmunity, Translational</i> MUTATIONS IN NOX3 AS GENETIC CAUSE OF FAMILIAL AGRANULOCYTOSIS DURING THYROSTATIC TREATMENT OF GRAVES' DISEASE Theo S. Plantinga , P. Arts, G.H. Knarren, A.H. Mulder, I.M. Wakelkamp, A. Hoischen, M. Netea, J. Smit, R.T. Netea-Maier | | |
| IDENTIFICATION OF NOVEL GENE FUSIONS BY TAI | id Cancer, Translational RGETED NEXT-GEN SEQUENCING IN THYROID FNA Zhong, A. Wald, L. Kelly, Y. Nikiforov | |
| Short Call Oral 6, <i>Thyroid Hormone Action, Basic</i> A ROLE FOR THYROID HORMONE ACTIVATION IN THE TREATMENT OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD) Meredith D. Hartley , <i>T. Banerji, T.S. Scanlan</i> | | |
| | 9:30 AM – 1:30 PM he Exhibit Hall 10:30 AM – 11:30 AM | |
| | s (5 total) 11:30 AM – 12:30 PM | |
| Clinical | Basic/Translational | |
| Radioactive Iodine Therapy in Benign Goiter Laszlo Hegedus Correlating Outcomes with the Histological Description of Follicular Cell Derived Thyroid Cancers: What Is The Clinical Relevance? Ronald Ghossein and Victor Bernet Should BRAF Status Influence Initial Management | What is New for Thyroid Hormone Transporters Theo Visser ATA Basic Science Handbook Antonio Bianco | |
| Decisions in Differentiated Thyroid Cancer? Sally Carty | | |
| and Kepal Patel Lunch and Poster Review on Y | Your Own 12:30 PM – 1:25 PM | |
| ATA Expo Theater with MedImmune, Specialty Care Division of AstraZeneca 12:30 PM – 1:25 PM Clinical Considerations in Advanced Medullary Thyroid Cancer (MTC) Patient Management (Only U.S. health care professionals are permitted to attend this program; space limited – first come, first served; lunch served) Speaker: Kate Newbold Exhibit Hall Closes 1:30 PM | | |
| EXHIBIT TAIL CLOSES 1750 FW | | |

| 84th Annual Meeting of the ATA | | | |
|---|---|--|--|
| Saturday, November 1, 2014 (continued) | | | |
| Paul Starr Award Lecture: What Can a Clinician Contribute? 1:30 PM – 2:15 PM | | | |
| Introduction: Gregory Randolph | | | |
| Speaker: Gilbert Daniels Oral Abstract Sessions 2:20 PM – 3:20 PM | | | |
| | | | |
| Clinical (4 total) Chairs: Giuseppe Barbesino and Rebecca Leboeuf | Basic/Translational (4 total) Chairs: Sandra McLachlan and Yaron Tomer | | |
| Oral Abstract 219, Thyroid & Development, Clinical PREGNANCY OUTCOMES OF EXPOSURE TO METHIMAZOLE (POEM) STUDY: AN INTERIM REPORT Naoko Arata, A. Murashima, S. Ito, Y. Ohashi, H. Onose, K. Kosaki, R. Kosaki, J. Tajiri, N. Hamada, Y. Hidaka, S. Fukata, N. Momotani, S. Kubota, H. Yoshikawa Oral Abstract 220, Thyroid & Development, Translational IS SEVERITY OF HYPOTHYROIDISM AT BIRTH ASSOCIATED WITH ABNORMAL CORTICAL DEVELOPMENT IN CHILDREN WITH CONGENITAL HYPOTHYROIDISM? Joanne F. Rovet, H. Clairman, J. Lischinsky, J. Skocic Oral Abstract 221, Disorders of Thyroid Function, Clinical MYXEDEMA COMA DIAGNOSIS AND TREATMENT: A CASE SERIES OF 45 PATIENTS FROM 2004-2014 TREATED WITH 500MCG OF IV L-THYROXINE K.C. Wu, Caroline T. Nguyen, J.S. LoPresti, D.A. Cohen Oral Abstract 222, Disorders of Thyroid Function, Clinical HYPERTHYROIDISM INCIDENCE VARIATION IN AND AROUND FIRST AND SUBSEQUENT PREGNANCIES: A DANISH POPULATION-BASED STUDY S.L. Andersen, A. Carlé, J. Olsen, Peter Laurberg | Oral Abstract 215, <i>Thyroid Hormone Action, Basic</i> ROLES OF THYROID HORMONE-TARGET GENE HISTONE H3K79 METHYLTRANSFERASE DOT1L DURING EMBRYOGENESIS AND ADULT STEM CELL DEVELOPMENT Yun-Bo Shi Oral Abstract 216, <i>Thyroid & Development, Basic</i> THYROID HORMONE DRIVING LARVAL CELLS MAD: THE ROLE OF C-MYC GENE FAMILY IN THYROID HORMONE- DEPENDENT INTESTINAL STEM CELL DEVELOPMENT Thomas C. Miller, M. Okada, Y. Shi Oral Abstract 217, <i>Thyroid & Development, Basic</i> THE HISTONE METHYLTRANSFERASE PRMT1 REGULATES ADULT INTESTINAL STEM CELL DEVELOPMENT IN MICE Julia Rodiger, Y. Zhang, Y. Shi Oral Abstract 218, Disorders of Thyroid Function, Basic XB130 DEFICIENCY RESULTS IN MOUSE THYROID HORMONE SYNTHESIS DISORDER Hiroki Shimizu, Y. Wang, H. Toba, H. Cho, X. Bai, S.L. Asa, X. Liao, S. Refetoff, M. Liu | | |
| | | | |
| | sia 3:25 PM – 4:40 PM | | |
| Clinical: Evolution of Imaging Modalities | Basic: Thyroid Hormone Receptors: | | |
| in Thyroid Cancer | Insights from Disease Models Chair: Graham Williams | | |
| Chairs: Anni Morsing and Ron Koenig | Chair: Granam williams | | |
| Update on Sonography in Thyroid Cancer Surveillance and | Prereceptor Defects in Humans | | |
| Novel Therapeutic Strategies for Nodal Metastases | Alexandra Dumitrescu | | |
| Robert Lee | THRA Human Mutations Carla Moran | | |
| FDG and Beyond: Evolution of Positron-Emission | THRB Human Mutations Samuel Refetoff | | |
| Tomography Tracers in Advanced Thyroid Cancers | | | |
| Trond Velde Bogsrud | | | |
| Personalized Approaches in Thyroid Cancer Imaging - The | | | |
| Future Anni Morsing | DM 4.55 DM | | |
| Break 4:40 F | PM – 4:55 PM | | |
| Symposium: More Everyday Ethical Dilemmas f | or Thyroid Practitioners 2014 4 55 PM – 6:10 PM | | |
| Symposium: More Everyday Ethical Dilemmas for Thyroid Practitioners 2014 4.55 PM – 6:10 PM <i>Moderator: Cheryl Fassler</i> | | | |
| | | | |
| Thyroidology and the Public Trust Loren Wissner Greene | | | |
| Informed Consent for Non-Standard or Innovative Therapies in Thyroidology M. Sara Rosenthal Mandatory Return of Results for the RET Mutations: New Ethical Dilemmas for the Thyroid World Peter Angelos | | | |
| FREE EVENING | | | |
| FREE E | | | |
| | | | |

84th Annual Meeting of the ATA Sunday, November 2, 2014

Registration Open 8:00 AM - 11:30 AM

Symposium: Contemporary Evaluation and Management of Thyroid Nodules

8:00 AM – 9:15 AM Chair: Melanie Goldfarb

Using Ultrasound to Risk Stratify Thyroid Nodules and Guide Selection for FNA Andrew Gianoukakis Rationale Follow-up of Cytologically Benign Thyroid Nodules Ralf Paschke Minimally Invasive Therapy for Benign and Malignant Nodules Enrico Papini

Thyroid Cancer Tumor Board 9:30 AM – 11:00 AM Moderator: Steven I. Sherman

Endocrinology: Douglas Ball Surgery: Ralph Tufano Nuclear Medicine: Daniel A. Pryma Radiation Oncology: James Brierley Oncology: Marcia Brose Pathology: Yuri Nikiforov

84th Annual Meeting Ends 11:00 AM



American Thyroid Association 6066 Leesburg Pike, Suite 550 Falls Church, VA 22041 Phone: 703-998-8890 Fax: 703-998-8893 Email: <u>thyroid@thyroid.org</u> Website: <u>www.thyroid.org</u>